Video

The Aftermath of Hepatitis C Drugs on Specialty Spending

Author(s):

Davy James, Managing Editor

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

Related Videos
Image credit: JJAVA | stock.adobe.com
Related Content
Las Vegas strip, Aerial view
April 25th 2025

Asembia's AXS25 Summit: Must-See Sessions, Expert Interviews as Specialty Pharmacy Gathers

Luke Halpern, Assistant Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Nasopharyngeal carcinoma -- Image credit: Matthieu | stock.adobe.com
April 24th 2025

FDA Approves Penpulimab-Kcqx for Indications in Nonkeratinizing Nasopharyngeal Carcinoma

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Hepatitis B virus blood test -- Image credit: gamjai | stock.adobe.com
April 24th 2025

Investigators Anticipate Hydronidone Will Be Beneficial for Liver Fibrosis in CHB

Gillian McGovern, Associate Editor
Image of kidneys without fibrosis -- Image credit: Itsaree | stock.adobe.com
April 24th 2025

Type 5 Collagen Linked to Kidney Scarring, Offers New Treatment Hope for Patients With CKD

Gillian McGovern, Associate Editor